SK288131B6 - CTLA4 mutant molecule or nucleic acid molecule, vector and host vector system, host cell, CTLA4 mutant protein, method for producing and use thereof, pharmaceutical composition and regulation method - Google Patents
CTLA4 mutant molecule or nucleic acid molecule, vector and host vector system, host cell, CTLA4 mutant protein, method for producing and use thereof, pharmaceutical composition and regulation method Download PDFInfo
- Publication number
- SK288131B6 SK288131B6 SK1570-2002A SK15702002A SK288131B6 SK 288131 B6 SK288131 B6 SK 288131B6 SK 15702002 A SK15702002 A SK 15702002A SK 288131 B6 SK288131 B6 SK 288131B6
- Authority
- SK
- Slovakia
- Prior art keywords
- ctla4
- ctla4 mutant
- molecule
- mutant molecule
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57992700A | 2000-05-26 | 2000-05-26 | |
US21406500P | 2000-06-26 | 2000-06-26 | |
PCT/US2001/017139 WO2001092337A2 (en) | 2000-05-26 | 2001-05-23 | Soluble ctla4 mutant molecules and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
SK15702002A3 SK15702002A3 (sk) | 2004-01-08 |
SK288131B6 true SK288131B6 (sk) | 2013-10-02 |
Family
ID=26908652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1570-2002A SK288131B6 (sk) | 2000-05-26 | 2001-05-23 | CTLA4 mutant molecule or nucleic acid molecule, vector and host vector system, host cell, CTLA4 mutant protein, method for producing and use thereof, pharmaceutical composition and regulation method |
Country Status (41)
Country | Link |
---|---|
EP (3) | EP3029062A1 (nl) |
JP (1) | JP4328525B2 (nl) |
KR (2) | KR100895134B1 (nl) |
CN (2) | CN1309735C (nl) |
AR (1) | AR031699A1 (nl) |
AT (1) | ATE271066T1 (nl) |
AU (2) | AU2001263466C1 (nl) |
BE (1) | BE2011C041I2 (nl) |
BR (1) | BRPI0111191B8 (nl) |
CA (1) | CA2409748C (nl) |
CY (2) | CY2011019I1 (nl) |
CZ (1) | CZ304451B6 (nl) |
DE (2) | DE60104282T2 (nl) |
DK (1) | DK1248802T3 (nl) |
EC (1) | ECSP024365A (nl) |
EE (2) | EE05458B1 (nl) |
EG (1) | EG24459A (nl) |
ES (2) | ES2225549T3 (nl) |
FR (1) | FR11C0053I2 (nl) |
GE (1) | GEP20053658B (nl) |
HK (2) | HK1048126B (nl) |
HU (2) | HU228137B1 (nl) |
IL (1) | IL152315A (nl) |
LT (1) | LT5133B (nl) |
LU (1) | LU91902I2 (nl) |
LV (1) | LV12994B (nl) |
MX (1) | MXPA02011534A (nl) |
MY (1) | MY136113A (nl) |
NO (2) | NO330797B1 (nl) |
PE (1) | PE20011338A1 (nl) |
PL (1) | PL206267B1 (nl) |
PT (1) | PT1248802E (nl) |
RU (1) | RU2283847C2 (nl) |
SI (1) | SI1248802T1 (nl) |
SK (1) | SK288131B6 (nl) |
TR (1) | TR200402703T4 (nl) |
TW (2) | TWI319405B (nl) |
UA (1) | UA87432C2 (nl) |
UY (1) | UY26723A1 (nl) |
WO (1) | WO2001092337A2 (nl) |
ZA (1) | ZA200208944B (nl) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
WO2002002638A2 (en) | 2000-07-03 | 2002-01-10 | Bristol-Myers Squibb Company | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
MXPA03010568A (es) | 2001-05-23 | 2005-03-07 | Squibb Bristol Myers Co | Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles. |
AU2003243152A1 (en) * | 2002-04-19 | 2003-11-03 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
DE10232697A1 (de) * | 2002-07-15 | 2004-02-05 | Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin | Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen |
ES2354610T5 (es) | 2002-12-23 | 2020-09-14 | Bristol Myers Squibb Co | Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína |
JP4541157B2 (ja) * | 2002-12-23 | 2010-09-08 | ブリストル−マイヤーズ スクイブ カンパニー | タンパク質を製造するための哺乳類細胞培養法 |
CA2511823A1 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
WO2005044188A2 (en) | 2003-10-27 | 2005-05-19 | Amgen Inc. | Compositions and methods to modulate an immune response to an immunogenic therapeutic agent |
AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
KR101398713B1 (ko) * | 2005-12-20 | 2014-06-12 | 브리스톨-마이어스 스큅 컴퍼니 | 조성물 및 조성물의 제조 방법 |
US7510844B2 (en) | 2006-01-24 | 2009-03-31 | Bristol-Myers Squibb Company | CD86 and CD80 receptor competition assays |
WO2008005290A2 (en) | 2006-06-29 | 2008-01-10 | The Trustees Of Columbia University In The City Of New York | Methods for testing anti-thrombotic agents |
GB0620934D0 (en) * | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
CN101675074B (zh) | 2006-12-20 | 2016-02-24 | Mmr全球公司 | 抗体及其制备和使用方法 |
CA2703263C (en) | 2007-11-01 | 2014-03-18 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
CA3038442A1 (en) * | 2008-10-02 | 2010-04-08 | Aptevo Research And Development Llc | Cd86 antagonist multi-target binding proteins |
US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
CN102822198B (zh) | 2010-03-12 | 2016-08-31 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
KR20130129438A (ko) | 2011-02-23 | 2013-11-28 | 암젠 인크 | Uvc 노출을 위한 세포 배양 배지 및 이와 관련된 방법 |
WO2013010537A1 (en) | 2011-07-20 | 2013-01-24 | Aarhus Universitet | Method of treating morphea |
WO2013148049A1 (en) * | 2012-03-29 | 2013-10-03 | The General Hospital Corporation | Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4) |
CN104302309B (zh) * | 2012-05-11 | 2017-07-28 | 米迪缪尼有限公司 | Ctla‑4变体 |
US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
KR20150033703A (ko) | 2012-06-27 | 2015-04-01 | 오르반 바이오테크 엘엘씨 | 당뇨병 치료를 위한 ctla4 융합 단백질 |
US20140112958A1 (en) | 2012-10-24 | 2014-04-24 | Mwm Biomodels Gmbh | Pancreatic islets of transgenic LEA29Y animals for treating diabetes |
CN104740608A (zh) * | 2013-12-30 | 2015-07-01 | 上海中信国健药业股份有限公司 | 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途 |
WO2015105609A1 (en) | 2014-01-13 | 2015-07-16 | Amgen Inc. | Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins |
GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
MX2016015944A (es) | 2014-06-04 | 2017-08-15 | Amgen Inc | Metodos para cosechar cultivos de celulas de mamifero. |
SG10202002458PA (en) | 2014-12-01 | 2020-04-29 | Amgen Inc | Process for manipulating the level of glycan content of a glycoprotein |
US10590457B2 (en) | 2015-02-11 | 2020-03-17 | Bristol Myers-Squibb Company | Compositions for cell culture and methods of using the same |
CA2982246A1 (en) | 2015-04-17 | 2016-10-20 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
WO2017044807A2 (en) | 2015-09-09 | 2017-03-16 | The Trustees Of Columbia University In The City Of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
US11401509B2 (en) | 2015-11-09 | 2022-08-02 | Bristol-Myers Squibb Company | Methods of minimizing glycoprotein agregation in CHO cell production |
CN116942793A (zh) * | 2016-09-19 | 2023-10-27 | 昂科医药 | Cd80和cd86结合蛋白组合物及其用途 |
CN107987153A (zh) * | 2016-10-27 | 2018-05-04 | 广东香雪精准医疗技术有限公司 | 高亲和力的可溶性pd-1分子 |
JP2020536552A (ja) | 2017-10-10 | 2020-12-17 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ctla−4変異型免疫調節タンパク質およびそれらの使用 |
CN109453383A (zh) * | 2018-11-12 | 2019-03-12 | 陈慧慧 | 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用 |
JP2022545917A (ja) | 2019-08-27 | 2022-11-01 | トニックス ファーマ リミテッド | 修飾tff2ポリペプチド |
SG11202110955VA (en) | 2019-12-06 | 2021-10-28 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
US20220011318A1 (en) | 2020-06-18 | 2022-01-13 | Regeneron Pharmaceuticals, Inc. | Heavy peptide approach to accurately measure unprocessed c-terminal lysine in antibodies |
US20230287322A1 (en) | 2020-07-28 | 2023-09-14 | Seagen Inc. | Methods and systems for producing polypeptides |
WO2023115027A2 (en) | 2021-12-16 | 2023-06-22 | Bristol-Myers Squibb Company | Detergent for viral inactivation |
WO2023167852A2 (en) | 2022-03-02 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Cell culture methods for antibody production |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
AU661854B2 (en) * | 1991-06-27 | 1995-08-10 | Bristol-Myers Squibb Company | CTL4A receptor, fusion proteins containing it and uses thereof |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
JP3521382B2 (ja) * | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
GB9809280D0 (en) * | 1998-04-30 | 1998-07-01 | Rpms Technology Ltd | Immunosupression |
CA2346496A1 (en) * | 1998-10-07 | 2000-04-13 | Millennium Pharmaceuticals, Inc. | Novel th2-specific molecules and uses thereof |
WO2002002638A2 (en) * | 2000-07-03 | 2002-01-10 | Bristol-Myers Squibb Company | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
-
2001
- 2001-05-23 GE GE4987A patent/GEP20053658B/en unknown
- 2001-05-23 IL IL152315A patent/IL152315A/en active Protection Beyond IP Right Term
- 2001-05-23 CN CNB018101453A patent/CN1309735C/zh not_active Expired - Lifetime
- 2001-05-23 WO PCT/US2001/017139 patent/WO2001092337A2/en not_active Application Discontinuation
- 2001-05-23 PT PT01937764T patent/PT1248802E/pt unknown
- 2001-05-23 UY UY26723A patent/UY26723A1/es not_active IP Right Cessation
- 2001-05-23 EP EP15197082.9A patent/EP3029062A1/en not_active Withdrawn
- 2001-05-23 PE PE2001000465A patent/PE20011338A1/es active IP Right Grant
- 2001-05-23 EG EG20010548A patent/EG24459A/xx active
- 2001-05-23 CN CNA2007100840790A patent/CN101255192A/zh active Pending
- 2001-05-23 HU HU0302201A patent/HU228137B1/hu active Protection Beyond IP Right Term
- 2001-05-23 SK SK1570-2002A patent/SK288131B6/sk not_active IP Right Cessation
- 2001-05-23 KR KR1020027015946A patent/KR100895134B1/ko active IP Right Grant
- 2001-05-23 RU RU2002131588/13A patent/RU2283847C2/ru active Protection Beyond IP Right Term
- 2001-05-23 EP EP04008908.8A patent/EP1536234B1/en not_active Expired - Lifetime
- 2001-05-23 EE EEP200200659A patent/EE05458B1/xx active Protection Beyond IP Right Term
- 2001-05-23 MX MXPA02011534A patent/MXPA02011534A/es active IP Right Grant
- 2001-05-23 AT AT01937764T patent/ATE271066T1/de active
- 2001-05-23 AU AU2001263466A patent/AU2001263466C1/en active Active
- 2001-05-23 DE DE60104282T patent/DE60104282T2/de not_active Expired - Lifetime
- 2001-05-23 UA UA20021210563A patent/UA87432C2/uk unknown
- 2001-05-23 KR KR1020077017691A patent/KR100889887B1/ko active IP Right Grant
- 2001-05-23 ES ES01937764T patent/ES2225549T3/es not_active Expired - Lifetime
- 2001-05-23 MY MYPI20012427A patent/MY136113A/en unknown
- 2001-05-23 CA CA002409748A patent/CA2409748C/en not_active Expired - Lifetime
- 2001-05-23 SI SI200130186T patent/SI1248802T1/xx unknown
- 2001-05-23 EE EEP201100050A patent/EE05557B1/xx unknown
- 2001-05-23 AU AU6346601A patent/AU6346601A/xx active Pending
- 2001-05-23 TW TW097137809A patent/TWI319405B/zh not_active IP Right Cessation
- 2001-05-23 ES ES04008908T patent/ES2571852T3/es not_active Expired - Lifetime
- 2001-05-23 DK DK01937764T patent/DK1248802T3/da active
- 2001-05-23 AR ARP010102449A patent/AR031699A1/es active IP Right Grant
- 2001-05-23 TR TR2004/02703T patent/TR200402703T4/xx unknown
- 2001-05-23 BR BR0111191-4 patent/BRPI0111191B8/pt not_active IP Right Cessation
- 2001-05-23 EP EP01937764A patent/EP1248802B9/en not_active Expired - Lifetime
- 2001-05-23 TW TW090112431A patent/TWI314933B/zh not_active IP Right Cessation
- 2001-05-23 JP JP2002500948A patent/JP4328525B2/ja not_active Expired - Lifetime
- 2001-05-23 CZ CZ2002-3892A patent/CZ304451B6/cs unknown
- 2001-05-23 PL PL366231A patent/PL206267B1/pl unknown
-
2002
- 2002-11-04 ZA ZA200208944A patent/ZA200208944B/en unknown
- 2002-11-13 LT LT2002114A patent/LT5133B/lt not_active IP Right Cessation
- 2002-11-25 NO NO20025656A patent/NO330797B1/no not_active IP Right Cessation
- 2002-11-26 EC EC2002004365A patent/ECSP024365A/es unknown
- 2002-12-19 LV LVP-02-214A patent/LV12994B/en unknown
-
2003
- 2003-01-09 HK HK03100239.8A patent/HK1048126B/zh not_active IP Right Cessation
-
2005
- 2005-06-21 HK HK05105135.0A patent/HK1071931A1/zh not_active IP Right Cessation
-
2011
- 2011-11-10 BE BE2011C041C patent/BE2011C041I2/fr unknown
- 2011-11-16 LU LU91902C patent/LU91902I2/fr unknown
- 2011-12-05 DE DE201112100063 patent/DE122011100063I1/de active Pending
- 2011-12-07 FR FR11C0053C patent/FR11C0053I2/fr active Active
- 2011-12-12 CY CY2011019C patent/CY2011019I1/el unknown
- 2011-12-15 NO NO2011027C patent/NO2011027I1/no not_active IP Right Cessation
-
2013
- 2013-04-12 HU HUS1300012C patent/HUS1300012I1/hu unknown
-
2016
- 2016-06-10 CY CY20161100511T patent/CY1117625T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210115107A1 (en) | Methods of treatment using ctla4 molecules | |
JP4328525B2 (ja) | 可溶性ctla4突然変異体分子およびその用途 | |
DK1935427T3 (en) | APPLICATIONS OF SOLUBLE, MUTANT CTLA4 MOLECULES | |
AU2006203199B2 (en) | Soluble CTLA4 mutant molecules and uses thereof | |
DK1536234T3 (en) | SOLUBLE MUTANT CTLA4 MOLECULES AND APPLICATIONS THEREOF | |
NZ542231A (en) | Soluble CTLA4 mutant fusion molecules and uses thereof | |
BG107210A (bg) | Разтворими ctla4 мутантни молекули и тяхното използване |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of an spc |
Free format text: PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: EU/1/11/694/001 - EU/1/11/694/002 20110617 Spc suppl protection certif: 5004-2014 Filing date: 20140210 |
|
SPCG | Grant of an spc |
Free format text: PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: EU/1/11/694/001 - EU/1/11/694/002 20110617 Spc suppl protection certif: 152 5004-2014 Filing date: 20140210 Extension date: 20260524 |
|
MK4A | Patent expired |
Expiry date: 20210523 |